{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:43:13Z","timestamp":1787510593820,"version":"build-2736575974"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      To validate the recently published 5-point PRIMARY scoring system against a 5-point European Association of Nuclear Medicine (E-PSMA) Likert system for the detection of intraprostatic recurrence for patients undergoing [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 PET\/CT who have previously received radiotherapy for prostate cancer as their primary treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      Thirty-five patients from one centre were investigated for suspected radiorecurrence between 2016 and 2022. All patients underwent multiparametric MRI and [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 PET\/CT for staging, then prostate biopsy. Analyses were performed at the hemi-gland level. Two expert readers, blinded to other clinical, pathologic, and radiologic data, independently assigned each hemi-gland an E-PSMA Likert and PRIMARY score. Outcomes were comparative diagnostic accuracy metrics and interreader agreement for each system at the hemi-gland level. Scores of 3\u20135 were considered suspicious for intraprostatic cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of 70 hemi-glands, 43 (61%) had cancer on biopsy. Area under the curve was high and not statistically significantly different between systems (E-PSMA Likert: 0.84; 95% CI: 0.74\u20130.92; PRIMARY: 0.82; 95% CI: 0.71\u20130.91;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.7). Sensitivity for E-PSMA Likert was 0.89 (95% CI: 0.78\u20130.96), not statistically different compared with the PRIMARY system (0.79; 95% CI: 0.67\u20130.89;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.3). Specificity for the E-PSMA Likert system was 0.67 (95% CI: 0.46\u20130.86), not statistically different compared with the PRIMARY system (0.78; 95% CI: 0.60\u20130.91;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.1). There was substantial interreader agreement between each reader for both E-PSMA Likert (\u03ba = 0.65; 95% CI: 0.44\u20130.83) and PRIMARY systems (\u03ba = 0.74; 95% CI: 0.59\u20130.90).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In patients with biochemical recurrence after primary radiotherapy for prostate cancer, both the 5-point PRIMARY and E-PSMA Likert scoring systems score demonstrated good performance and substantial interreader agreement between experts for the detection of intraprostatic recurrences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006168","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T01:00:10Z","timestamp":1765328410000},"page":"e1-e10","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Validation of the PSMA PRIMARY Scoring System and Comparison to an E-PSMA Likert System for [68Ga]Ga-PSMA-11 PET\/CT Interpretation in Men With Suspected Radiorecurrent Prostate Cancer"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7246-3651","authenticated-orcid":false,"given":"Alexander","family":"Light","sequence":"first","affiliation":[{"name":"Imperial Prostate, Department of Surgery and Cancer, Imperial College London"},{"name":"Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Lazic","sequence":"additional","affiliation":[{"name":"Department of Imaging, Charing Cross Hospital, Imperial College Healthcare NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4033-7508","authenticated-orcid":false,"given":"Martin J.","family":"Connor","sequence":"additional","affiliation":[{"name":"Imperial Prostate, Department of Surgery and Cancer, Imperial College London"},{"name":"Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Imaging, Charing Cross Hospital, Imperial College Healthcare NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-6723","authenticated-orcid":false,"given":"Hashim U.","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Imperial Prostate, Department of Surgery and Cancer, Imperial College London"},{"name":"Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1642-1208","authenticated-orcid":false,"given":"Taimur T.","family":"Shah","sequence":"additional","affiliation":[{"name":"Imperial Prostate, Department of Surgery and Cancer, Imperial College London"},{"name":"Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara D.","family":"Barwick","sequence":"additional","affiliation":[{"name":"Department of Imaging, Charing Cross Hospital, Imperial College Healthcare NHS Trust"},{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"R1-20251210","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2023.41.6_suppl.304","article-title":"10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK\/06\/016)","volume":"41","author":"Syndikus","year":"2023","journal-title":"Am Soc Clin Oncol"},{"key":"R3-20251210","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.eururo.2022.07.011","article-title":"Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN)","volume":"82","author":"Ma","year":"2022","journal-title":"Eur Urol"},{"key":"R4-20251210","doi-asserted-by":"crossref","first-page":"296.e21","DOI":"10.1016\/j.urolonc.2020.11.002","article-title":"Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: a multicenter retrospective study","volume":"39","author":"Marra","year":"2021","journal-title":"Urol Oncol"},{"key":"R5-20251210","doi-asserted-by":"crossref","DOI":"10.1007\/s11934-017-0709-4","article-title":"Salvage therapy options for local prostate cancer recurrence after primary radiotherapy: a literature review","volume":"18","author":"Golbari","year":"2017","journal-title":"Curr Urol Rep"},{"key":"R6-20251210","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"R7-20251210","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.eururo.2022.02.022","article-title":"Magnetic resonance imaging and targeted biopsies compared to transperineal mapping biopsies before focal ablation in localised and metastatic recurrent prostate cancer after radiotherapy","volume":"81","author":"Shah","year":"2022","journal-title":"Eur Urol Elsevier BV"},{"key":"R8-20251210","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bju.13831","article-title":"Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer","volume":"120","author":"Kanthabalan","year":"2017","journal-title":"BJU Int"},{"key":"R9-20251210","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/bju.14838","article-title":"Salvage high-intensity focused ultrasound for locally recurrent prostate cancer after low-dose-rate brachytherapy: oncological and functional outcomes","volume":"124","author":"Hostiou","year":"2019","journal-title":"BJU Int"},{"key":"R10-20251210","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/j.clgc.2019.11.009","article-title":"Salvage Focal cryotherapy offers similar short-term oncologic control and improved urinary function compared with salvage whole gland cryotherapy for radiation-resistant or recurrent prostate cancer","volume":"18","author":"Tan","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"R11-20251210","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.21037\/tau.2019.08.21","article-title":"A systematic review of salvage focal therapies for localised non-metastatic radiorecurrent prostate cancer","volume":"9","author":"Khoo","year":"2020","journal-title":"Transl Androl Urol"},{"key":"R12-20251210","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"key":"R15-20251210","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41585-022-00635-9","article-title":"The unclear role of PET-CT in localized radiorecurrent prostate cancer","volume":"19","author":"Light","year":"2022","journal-title":"Nat Rev Urol"},{"key":"R16-20251210","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"R17-20251210","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bju.15135","article-title":"68 Ga-PSMA-PET\/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer","volume":"126","author":"Pfister","year":"2020","journal-title":"BJU Int"},{"key":"R18-20251210","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41391-019-0163-0","article-title":"The use of 68Ga-PET\/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy","volume":"22","author":"Raveenthiran","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R19-20251210","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2967\/jnumed.119.231654","article-title":"Prospective evaluation of 18F-DCFPyL PET\/CT in biochemically recurrent prostate cancer in an academic center: a focus on disease localization and changes in management","volume":"61","author":"Song","year":"2020","journal-title":"J Nucl Med"},{"key":"R20-20251210","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030781","article-title":"Value of targeted biopsies and combined PSMA PET\/CT and mp-MRI imaging in locally recurrent prostate cancer after primary radiotherapy","volume":"14","author":"Rasing","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R21-20251210","article-title":"Diagnostic performance of 68Ga-PSMA-11 PET\/CT versus multiparametric MRI for detection of intraprostatic radiorecurrent prostate cancer","volume":"00","author":"Light","year":"2024","journal-title":"J Nucl Med"},{"key":"R22-20251210","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R23-20251210","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"R24-20251210","first-page":"1644","article-title":"The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"R25-20251210","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2967\/jnumed.123.266164","article-title":"Reproducibility and accuracy of the PRIMARY score on PSMA PET and of PI-RADS on multiparametric MRI for prostate cancer diagnosis within a real-world database","volume":"65","author":"Emmett","year":"2024","journal-title":"J Nucl Med"},{"key":"R26-20251210","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol Elsevier"},{"key":"R27-20251210","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R28-20251210","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000003890","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"R29-20251210","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"R30-20251210","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","article-title":"Robust locally weighted regression and smoothing scatterplots","volume":"74","author":"Cleveland","year":"1979","journal-title":"J Am Stat Assoc"},{"key":"R31-20251210","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics JSTOR"},{"key":"R32-20251210","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/0962280214541852","article-title":"Does McNemar\u2019s test compare the sensitivities and specificities of two diagnostic tests?","volume":"26","author":"Kim","year":"2017","journal-title":"Stat Methods Med Res"},{"key":"R33-20251210","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.0006-341X.2000.00345.x","article-title":"Comparisons of predictive values of binary medical diagnostic tests for paired designs","volume":"56","author":"Leisenring","year":"2000","journal-title":"Biometrics"},{"key":"R34-20251210","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"R35-20251210","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/RLU.0000000000004524","article-title":"High interobserver agreement on PSMA PET\/CT even in the absence of clinical data","volume":"48","author":"Bundschuh","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R36-20251210","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00330-023-10083-7","article-title":"Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET\/CT scans in prostate cancer patients","volume":"34","author":"Grawe","year":"2024","journal-title":"Eur Radiol"},{"key":"R37-20251210","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00259-024-06594-0","article-title":"The accuracy and intra- and interobserver variability of PSMA PET\/CT for the local staging of primary prostate cancer","volume":"51","author":"Donswijk","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R38-20251210","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1148\/radiol.13122233","article-title":"Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales","volume":"269","author":"Rosenkrantz","year":"2013","journal-title":"Radiology"},{"key":"R39-20251210","doi-asserted-by":"crossref","DOI":"10.1186\/s12894-015-0087-5","article-title":"Five-point Likert scaling on MRI predicts clinically significant prostate carcinoma","volume":"15","author":"Harada","year":"2015","journal-title":"BMC Urol"},{"key":"R40-20251210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bju.13972","article-title":"Diagnostic accuracy of a five-point Likert scoring system for magnetic resonance imaging (MRI) evaluated according to results of MRI\/ultrasonography image-fusion targeted biopsy of the prostate","volume":"121","author":"Shin","year":"2018","journal-title":"BJU Int"},{"key":"R41-20251210","doi-asserted-by":"crossref","first-page":"651","DOI":"10.5455\/annalsmedres.2018.08.157","article-title":"Comparison of Likert and PI-RADS v2 scoring in the diagnosis of prostate cancer","volume":"25","author":"Inan","year":"2018","journal-title":"Ann Med Res ScopeMed"},{"key":"R42-20251210","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200298","article-title":"Comparison of Likert and PI-RADS version 2 MRI scoring systems for the detection of clinically significant prostate cancer","volume":"93","author":"Zawaideh","year":"2020","journal-title":"Br J Radiol"},{"key":"R43-20251210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/bju.14916","article-title":"Likert vs PI-RADS v2: a comparison of two radiological scoring systems for detection of clinically significant prostate cancer","volume":"125","author":"Khoo","year":"2020","journal-title":"BJU Int"},{"key":"R45-20251210","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2967\/jnumed.117.190827","article-title":"68Ga-PSMA-11 PET\/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study","volume":"58","author":"Fendler","year":"2017","journal-title":"J Nucl Med"},{"key":"R46-20251210","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00259-020-04945-1","article-title":"False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial","volume":"48","author":"Fendler","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R47-20251210","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.euo.2021.01.003","article-title":"Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy","volume":"4","author":"Panebianco","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"R48-20251210","first-page":"7","article-title":"Development and internal validation of multivariable prediction models for biochemical failure after MRI-guided focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer","volume":"30","author":"Willigenburg","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"R49-20251210","doi-asserted-by":"crossref","first-page":"13.e1","DOI":"10.1016\/j.urolonc.2017.08.022","article-title":"Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses","volume":"36","author":"Peters","year":"2018","journal-title":"Urol Oncol"},{"key":"R51-20251210","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jclinepi.2022.01.022","article-title":"Studies of diagnostic test accuracy: partial verification bias and test result-based sampling","volume":"145","author":"Kohn","year":"2022","journal-title":"J Clin Epidemiol Pergamon"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:00:41Z","timestamp":1765371641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006168","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"2025-06-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}